$CRSP
CRISPR Therapeutics AG

2021 Q4 Form 10-K Financial Statement

#000095017022001282 Filed on February 15, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $12.90M $915.0M $370.0K
YoY Change 3386.22% 127154.94% -99.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $24.13M $102.8M $25.80M
YoY Change -6.48% 16.56% 49.13%
% of Gross Profit
Research & Development $134.5M $438.6M $82.40M
YoY Change 63.19% 64.32% 68.85%
% of Gross Profit
Depreciation & Amortization $6.261M $17.95M $2.560M
YoY Change 144.57% 95.48% 77.78%
% of Gross Profit
Operating Expenses $158.6M $541.4M $108.1M
YoY Change 46.67% 52.45% 63.75%
Operating Profit $373.5M -$107.8M
YoY Change -205.39% -1081.16%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit 0.0%
Other Income/Expense, Net $2.197M $6.003M $600.0K
YoY Change 266.17% -5.89% -96.94%
Pretax Income -$143.5M $379.5M -$107.2M
YoY Change 33.86% -209.04% -451.48%
Income Tax -$2.253M $1.870M -$100.0K
% Of Pretax Income 0.49%
Net Earnings -$141.2M $377.7M -$107.0M
YoY Change 31.96% -208.25% -450.46%
Net Earnings / Revenue -1095.03% 41.28% -28929.46%
Basic Earnings Per Share $4.97 -$1.50
Diluted Earnings Per Share -$1.843M $4.70 -$1.50
COMMON SHARES
Basic Shares Outstanding 76.53M 75.95M 71.28M
Diluted Shares Outstanding 80.39M 71.28M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.329B $2.379B $1.169B
YoY Change 13.66% 40.75% 23.86%
Cash & Equivalents $923.0M $1.169B
Short-Term Investments $405.6M $1.456B $395.1K
Other Short-Term Assets $38.08M $38.08M $26.10M
YoY Change 45.9% 45.9% -40.27%
Inventory
Prepaid Expenses
Receivables $305.0K $305.0K $144.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.418B $2.418B $1.717B
YoY Change 40.83% 40.83% 73.83%
LONG-TERM ASSETS
Property, Plant & Equipment $137.6M $312.0M $42.16M
YoY Change 226.32% 235.52% 34.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.291M $22.20M $1.293M
YoY Change 309.2% 22.67% 17.87%
Total Long-Term Assets $334.4M $334.4M $111.3M
YoY Change 200.29% 200.15% 40.58%
TOTAL ASSETS
Total Short-Term Assets $2.418B $2.418B $1.717B
Total Long-Term Assets $334.4M $334.4M $111.3M
Total Assets $2.752B $2.752B $1.828B
YoY Change 50.54% 50.54% 71.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.82M $14.82M $9.094M
YoY Change 62.92% 62.81% 52.99%
Accrued Expenses $91.00M $103.2M $53.78M
YoY Change 69.21% 58.47% 78.2%
Deferred Revenue $1.011M $2.341M
YoY Change -56.81% 143.85%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $119.9M $119.9M $94.26M
YoY Change 27.18% 27.13% 65.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.339M $232.5M $7.630M
YoY Change -3.81% 234.58% -47.0%
Total Long-Term Liabilities $7.339M $232.5M $7.630M
YoY Change -3.81% 234.58% -47.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $119.9M $119.9M $94.26M
Total Long-Term Liabilities $7.339M $232.5M $7.630M
Total Liabilities $352.4M $352.4M $163.7M
YoY Change 115.24% 115.28% 28.59%
SHAREHOLDERS EQUITY
Retained Earnings -$195.9M -$573.6M
YoY Change -65.84% 155.25%
Common Stock $2.601B $2.238B
YoY Change 16.2% 92.23%
Preferred Stock
YoY Change
Treasury Stock (at cost) $63.00K $63.00K
YoY Change 0.0% 0.0%
Treasury Stock Shares $180.3K $195.3K
Shareholders Equity $2.399B $2.399B $1.664B
YoY Change
Total Liabilities & Shareholders Equity $2.752B $2.752B $1.828B
YoY Change 50.54% 50.54% 71.36%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$141.2M $377.7M -$107.0M
YoY Change 31.96% -208.25% -450.46%
Depreciation, Depletion And Amortization $6.261M $17.95M $2.560M
YoY Change 144.57% 95.48% 77.78%
Cash From Operating Activities -$86.04M $539.0M -$81.22M
YoY Change 5.93% -326.11% -2502.96%
INVESTING ACTIVITIES
Capital Expenditures -$9.183M $81.71M -$6.240M
YoY Change 47.16% 345.06% 556.84%
Acquisitions
YoY Change
Other Investing Activities $467.0K -$953.7M -$198.0M
YoY Change -100.24% 82.42% -2571.91%
Cash From Investing Activities -$8.716M -$1.035B -$204.2M
YoY Change -95.73% 91.33% -2992.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $213.3M
YoY Change -78.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.299M 250.9M 412.6M
YoY Change -98.47% -75.3% 35.41%
NET CHANGE
Cash From Operating Activities -86.04M 539.0M -81.22M
Cash From Investing Activities -8.716M -1.035B -204.2M
Cash From Financing Activities 6.299M 250.9M 412.6M
Net Change In Cash -88.46M -245.5M 127.2M
YoY Change -169.56% -203.75% -59.65%
FREE CASH FLOW
Cash From Operating Activities -$86.04M $539.0M -$81.22M
Capital Expenditures -$9.183M $81.71M -$6.240M
Free Cash Flow -$76.86M $457.3M -$74.98M
YoY Change 2.5% -278.12% -1831.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001674416
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
923031000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1168620000
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37923
CY2021 dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
V8
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
Baarerstrasse 14
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
11400000000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77067587
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021 dei Entity Address Country
EntityAddressCountry
CH
CY2021 dei City Area Code
CityAreaCode
41 (0)41
CY2021 dei Local Phone Number
LocalPhoneNumber
561 32 77
CY2021 dei Security12b Title
Security12bTitle
Common Shares, nominal value CHF 0.03
CY2021 dei Trading Symbol
TradingSymbol
CRSP
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1456098000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
521713000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
305000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
144000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38079000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
26143000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2417513000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1716620000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
137575000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42160000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
125000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
180000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16913000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16848000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
174460000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
50865000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5291000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1293000
CY2021Q4 us-gaap Assets
Assets
2751877000
CY2020Q4 us-gaap Assets
Assets
1827966000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14816000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9094000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91003000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53782000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1011000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2341000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
724000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
10473000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12158000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11362000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
171000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7207000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
119883000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
94259000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12323000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
11776000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
212872000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
50067000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7339000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7630000
CY2021Q4 us-gaap Liabilities
Liabilities
352417000
CY2020Q4 us-gaap Liabilities
Liabilities
163732000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77170382
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74110160
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76990066
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73914844
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2391000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2277000
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
180316
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
195316
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2598114000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2235679000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-195915000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-573576000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5067000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-83000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2399460000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1664234000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2751877000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1827966000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
914963000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
719000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
289590000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
438633000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
266946000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
179362000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
102802000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
88208000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
63488000
CY2021 us-gaap Operating Expenses
OperatingExpenses
541435000
CY2020 us-gaap Operating Expenses
OperatingExpenses
355154000
CY2019 us-gaap Operating Expenses
OperatingExpenses
242850000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
373528000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-354435000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
46740000
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-5467000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6003000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6379000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
26033000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6003000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6379000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20566000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
379531000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-348056000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
67306000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1870000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
809000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
448000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
377661000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-348865000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
66858000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-11000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
40000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
15000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4973000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-130000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
372677000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-348955000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
66873000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.97
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.29
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.23
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75948686
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65949672
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54392304
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.70
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.29
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.17
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80393496
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65949672
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56932798
CY2019 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
746000
CY2019 crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
14459000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
392195000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
414789000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
43000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16001000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
49524000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
66858000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
939425000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
973381000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
7000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32775000
CY2020 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
694000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
66018000
CY2020 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
889000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-90000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-348865000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1664234000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
222175000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
15000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35874000
CY2021 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
2095000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
102390000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4984000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
377661000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2399460000
CY2021 us-gaap Profit Loss
ProfitLoss
377661000
CY2020 us-gaap Profit Loss
ProfitLoss
-348865000
CY2019 us-gaap Profit Loss
ProfitLoss
66858000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17953000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9184000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4725000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
102390000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
66018000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
44057000
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-5467000
CY2019 crsp Gain Loss From Consolidation Of Subsidiary
GainLossFromConsolidationOfSubsidiary
16000000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-14109000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1857000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
161000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
45000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
213267000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13912000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17338000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
32618000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
37514000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
25747000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5025000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-783000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1381000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-45146000
CY2021 crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
9506000
CY2020 crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-473000
CY2019 crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-663000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-5305000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-10508000
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
24983000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
538972000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-238366000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
56677000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
81705000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18358000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6684000
CY2019 crsp Net Cash And Restricted Cash Received In Connection With Acquisition Of Controlling Interest
NetCashAndRestrictedCashReceivedInConnectionWithAcquisitionOfControllingInterest
8009000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1509327000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
593998000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
555602000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
71186000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1035430000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-541170000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1325000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
982289000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
415019000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
37678000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
33863000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
15964000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
250945000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1016152000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
430983000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-11000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-245524000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
236656000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
489000000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1185468000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
948812000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
459812000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
939944000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1185468000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
948812000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8348000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3412000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1811000
CY2021 crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
334000
CY2020 crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
9590000
CY2019 crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
295000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
923031000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1168620000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
943771000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16913000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16848000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5041000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
939944000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1185468000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
948812000
CY2021 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2013-10-31
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-195900000
CY2021Q4 crsp Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
2379100000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
923000000.0
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1168600000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16900000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1456100000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
521700000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk and Off-balance Sheet Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company’s cash is held in accounts with financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
12300000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
12200000
CY2021Q4 crsp Uncertain Tax Position Recognized
UncertainTaxPositionRecognized
0
CY2020Q4 crsp Uncertain Tax Position Recognized
UncertainTaxPositionRecognized
0
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
405600
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
395100
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
517383000
CY2021Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
1000
CY2021Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
517382000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1461200000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5118000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1456098000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1978583000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
16000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
5119000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1973480000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
773560000
CY2020Q4 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
1000
CY2020Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
24000
CY2021 us-gaap Depreciation
Depreciation
17900000
CY2020 us-gaap Depreciation
Depreciation
9100000
CY2019 us-gaap Depreciation
Depreciation
4700000
CY2020Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
773537000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
521820000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
51000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
158000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
521713000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1295380000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
52000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
182000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1295250000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1311600
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
280300000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
4600
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
175382000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
63335000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37807000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21175000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
137575000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42160000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
151000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
59000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23661000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22402000
CY2021Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
47986000
CY2020Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
21684000
CY2021Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
138000
CY2020Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
1401000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4720000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1670000
CY2021Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
6120000
CY2020Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
3625000
CY2021Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
7113000
CY2020Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
2835000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1265000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
165000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91003000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53782000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
174460000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
50865000
CY2021Q4 crsp Lease Assets
LeaseAssets
174460000
CY2020Q4 crsp Lease Assets
LeaseAssets
50865000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12158000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11362000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
212872000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
50067000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
225030000
CY2020 us-gaap Sublease Income
SubleaseIncome
587000
CY2019 us-gaap Sublease Income
SubleaseIncome
525000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
61429000
CY2021 us-gaap Lease Cost
LeaseCost
36756000
CY2020 us-gaap Lease Cost
LeaseCost
27462000
CY2019 us-gaap Lease Cost
LeaseCost
16378000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
22520000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
14342000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
8067000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
11087000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
7339000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4554000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
8402000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
6368000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
4282000
CY2021 us-gaap Sublease Income
SubleaseIncome
5253000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
18256000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
26633000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
26137000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
26347000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
26844000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
227528000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
351745000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
126715000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
225030000
CY2021Q4 crsp Operating Lease Assets Fair Value Disclosure
OperatingLeaseAssetsFairValueDisclosure
11003000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y4M24D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.059
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.093
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
19753000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
13161000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
8420000
CY2021 crsp Right Of Use Assets Increased Through Lease Modifications And Reassessments
RightOfUseAssetsIncreasedThroughLeaseModificationsAndReassessments
-14230000
CY2020 crsp Right Of Use Assets Increased Through Lease Modifications And Reassessments
RightOfUseAssetsIncreasedThroughLeaseModificationsAndReassessments
3169000
CY2019 crsp Right Of Use Assets Increased Through Lease Modifications And Reassessments
RightOfUseAssetsIncreasedThroughLeaseModificationsAndReassessments
826000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
152486000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13956000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
18088000
CY2021 crsp Leasehold Improvements Paid Directly By Landlord
LeaseholdImprovementsPaidDirectlyByLandlord
30500000
CY2021 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
5800000
CY2020 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
4500000
CY2019 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
2900000
CY2021 crsp Cost Sharing Expenses Accrued
CostSharingExpensesAccrued
4000000.0
CY2020 crsp Cost Sharing Expenses Accrued
CostSharingExpensesAccrued
2500000
CY2021 crsp Joint Venture Agreement Date
JointVentureAgreementDate
2015-12-19
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6784000
CY2021Q4 crsp Prepaid Expenses And Other Current Assets Fair Value Disclosure
PrepaidExpensesAndOtherCurrentAssetsFairValueDisclosure
2565000
CY2021Q4 us-gaap Property Plant And Equipment Fair Value Disclosure
PropertyPlantAndEquipmentFairValueDisclosure
9340000
CY2021Q4 crsp Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
1226000
CY2021Q4 crsp Accrued Expenses And Other Current Liabilities Fair Value Disclosure
AccruedExpensesAndOtherCurrentLiabilitiesFairValueDisclosure
3915000
CY2021Q4 crsp Operating Lease Liabilities Fair Value Disclosure
OperatingLeaseLiabilitiesFairValueDisclosure
11003000
CY2021Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
16000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1616255
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
124.32
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1616255
CY2021Q4 crsp Common Stock Registered Share Capital
CommonStockRegisteredShareCapital
80321227
CY2020Q4 crsp Common Stock Registered Share Capital
CommonStockRegisteredShareCapital
75133951
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5038262
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each common share
CY2021 us-gaap Dividends
Dividends
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
102400000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
66000000.0
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
49500000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
102390000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
66018000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
49524000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
150600000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2182773
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2832784
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
124.32
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
68.91
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
39.16
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
77.38
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
42.28
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
30.96
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1245071
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.57
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.703
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.692
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.689
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.006
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.022
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8101980
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.44
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
896666000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1000
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
660182
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
79.54
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7812982
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.07
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
219103000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4598353
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
40.86
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
174056000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7812982
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
58.07
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
219103000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
119500000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
104200000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
42200000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
377661000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-348865000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
66858000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75948686
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65949672
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54392304
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80393496
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65949672
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56932798
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.97
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.29
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.23
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.70
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.29
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.17
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1998456
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9007329
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3897754
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
3400000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1900000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
4569000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
7630000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
9155000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
374962000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-355686000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
58151000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
379531000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-348056000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
67306000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
80000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
248000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
423000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
42000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
122000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
400000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
1748000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
409000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-34000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1748000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
482000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
409000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-34000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1870000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
809000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
448000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.119
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.119
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.093
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.010
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.010
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.021
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.007
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.006
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.020
CY2021 crsp Effective Income Tax Rate Reconciliation Statutory Permanent Differences
EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences
0.000
CY2020 crsp Effective Income Tax Rate Reconciliation Statutory Permanent Differences
EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences
0.000
CY2019 crsp Effective Income Tax Rate Reconciliation Statutory Permanent Differences
EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences
0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.025
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.023
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.020
CY2021 crsp Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange
0.000
CY2020 crsp Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange
0.000
CY2019 crsp Effective Income Tax Rate Reconciliation Nondeductible Expense Impact Of Deferred Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpactOfDeferredRateChange
-0.122
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.042
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.033
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.052
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.050
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.187
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.109
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.007
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
47190000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
84531000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
5878000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
4785000
CY2021Q4 crsp Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
61476000
CY2020Q4 crsp Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
16782000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6362000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
74177000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
20192000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
28579000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
6778000
CY2021Q4 crsp Deferred Tax Liabilities Operating Lease Assets
DeferredTaxLiabilitiesOperatingLeaseAssets
47521000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1517000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
14042000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9605000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
86000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
37878000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
19526000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
172826000
CY2020Q4 crsp Deferred Tax Liabilities Operating Lease Assets
DeferredTaxLiabilitiesOperatingLeaseAssets
13776000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
136832000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
98649000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
116640000
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
31000
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
31000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
192000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
4000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
76323000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
20589000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2146000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
397000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-18000000.0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
3300000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
772900000
CY2021 crsp Operating Loss Carryforwards Expiration Period
OperatingLossCarryforwardsExpirationPeriod
2027
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
21400000
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
19900000
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 crsp Uncertain Tax Position Recognized
UncertainTaxPositionRecognized
0
CY2020Q4 crsp Uncertain Tax Position Recognized
UncertainTaxPositionRecognized
0
CY2019Q4 crsp Uncertain Tax Position Recognized
UncertainTaxPositionRecognized
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11967000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5231000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1595000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
9911000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
7004000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2754000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
882000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
483000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
268000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
21395000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11967000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5231000

Files In Submission

Name View Source Status
0000950170-22-001282-index-headers.html Edgar Link pending
0000950170-22-001282-index.html Edgar Link pending
0000950170-22-001282.txt Edgar Link pending
0000950170-22-001282-xbrl.zip Edgar Link pending
crsp-20211231.htm Edgar Link pending
crsp-20211231.xsd Edgar Link pending
crsp-20211231_cal.xml Edgar Link unprocessable
crsp-20211231_def.xml Edgar Link unprocessable
crsp-20211231_htm.xml Edgar Link completed
crsp-20211231_lab.xml Edgar Link unprocessable
crsp-20211231_pre.xml Edgar Link unprocessable
crsp-ex10_32.htm Edgar Link pending
crsp-ex10_37.htm Edgar Link pending
crsp-ex21_1.htm Edgar Link pending
crsp-ex23_1.htm Edgar Link pending
crsp-ex31_1.htm Edgar Link pending
crsp-ex31_2.htm Edgar Link pending
crsp-ex32_1.htm Edgar Link pending
crsp-ex4_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img166603869_0.jpg Edgar Link pending
img166603869_1.jpg Edgar Link pending
img166603869_10.jpg Edgar Link pending
img166603869_11.jpg Edgar Link pending
img166603869_12.jpg Edgar Link pending
img166603869_13.jpg Edgar Link pending
img166603869_14.jpg Edgar Link pending
img166603869_15.jpg Edgar Link pending
img166603869_16.jpg Edgar Link pending
img166603869_17.jpg Edgar Link pending
img166603869_18.jpg Edgar Link pending
img166603869_19.jpg Edgar Link pending
img166603869_2.jpg Edgar Link pending
img166603869_20.jpg Edgar Link pending
img166603869_21.jpg Edgar Link pending
img166603869_3.jpg Edgar Link pending
img166603869_4.jpg Edgar Link pending
img166603869_5.jpg Edgar Link pending
img166603869_6.jpg Edgar Link pending
img166603869_7.jpg Edgar Link pending
img166603869_8.jpg Edgar Link pending
img166603869_9.jpg Edgar Link pending
img9701982_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending